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: Process for the preparation of crystal modification 3 of (R)-3-(4

Process for the preparation of crystal modification 3 of (R)-3-(4-(7H-pyrrolo[2,3d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile hydrochloride
Abstract:
Process

for

the

preparation

of

crystal

modification

3

of

(R)-3-(4-(7H-

pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile hydrochloride of
formula-1, which is represented by the following structural formula:

Introduction:
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropane
nitrile is commonly known as Ruxolitinib, which is a selective inhibitor of Janus Associated
Kinase 1 (JAK1) and JAK2 which mediates the signalling of a number of cytokines and growth
factors that are important for haematopoiesis and immune function.
Ruxolitinib phosphate is approved under the brand name Jakafi in the USFDA and
Jakavi in Europe for the treatment of patients with intermediate or high-risk myelofibrosis,
including primary myelofibrosis, postpolycythemia vera myelofibrosis and postessential
thrombocythemia myelofibrosis.
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropane
nitrile or a pharmaceutically acceptable salt is disclosed in US7598257 B2.
Disclosed herein the process for the preparation of crystal modification 3 of (R)-3-(4(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
hydrochloride of formula-1, schematically as mentioned below:
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The compounds of Formulae 6 and 7 used in the present invention are prepared by
method reported in US7598257 B2 or any other methods known in the art.
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Experimental Section:
Example-1: Preparation of (R)-3-cyclopentyl-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile

(2S,3S)-2,3-

bis(benzoyloxy)succinate of Formula-4.
Acetonitrile

(500.0

ml)

was

added

to

4-(1H-pyrazol-4-yl)-7-((2-

(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine of formula-7 (100.0 gm) at 2530ºC. Potassium carbonate (131.0 gm) and (E)-3-cyclopentylacrylonitrile of formula-6 (46.0
ml) were added to mixture at 25-30ºC. Heated the mixture to 80-85ºC and stirred for 4 hours.
Cooled the mixture to 25-30ºC. Filtered the mixture through hyflow bed and washed the hyflow
bed with acetonitrile. Distilled off the solvent completely from the filtrate under vacuum at
below 60-65ºC and co-distilled with methanol.
Methanol (1000.0 ml) was added to the obtained compound at 50-55ºC and stirred for
10 minutes. (+)-Dibenzoyl-D-tartaric acid monohydrate (131.0 gm) was added to the mixture
at 50-55ºC. Raised the temperature of the mixture to reflux and stirred for 90 minutes. Cooled
the mixture to 25-30ºC and stirred for 90 minutes. Cooled the mixture to 0-5ºC and stirred for
90 minutes. Filtered the solid and washed with isopropanol. Ethyl acetate (450.0 ml) was added
to the obtained compound at 25-30ºC and stirred for 10 minutes. 10% Sodium carbonate
solution was added to the mixture at 25-30ºC and stirred for 10 minutes. Layers were separated.
Distilled off the organic layer at below 60ºC under vacuum and co-distilled with methanol.
Repeat the same process multiple time. Methanol (350.0 ml) was added to the obtained
compound at 50-55ºC and stirred for 10 minutes. (+)-Dibenzoyl-D-tartaric acid monohydrate
(42.0 gm) was added to the mixture at 50-55ºC. Raised the temperature of the mixture to reflux
and stirred for 90 minutes. Cooled the mixture to 25-30ºC and stirred for 90 minutes. Cooled
the mixture to 0-5ºC and stirred for 90 minutes. Filtered the solid, washed with isopropanol
and dried to get the title compound. Yield: 62.0 gm.
Example-2:

Preparation

of

crystal

modification

3

of

(R)-3-(4-(7H-

pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
hydrochloride of Fotmula-1.
Water (200.0 ml) and dichloromethane (300.0 ml) were added to (R)-3-(4-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

phosphate

of

formula-3 (20.0 gm) at 25-30ºC and stirred for 30 minutes. Sodium carbonate solution was
added to mixture at 25-30ºC and stirred for 20 minutes. Layers were separated. Water (100.0
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ml) was added to organic layer at 25-30ºC and stirred for 20 minutes. Layers were separated.
Water (100.0 ml) was added to organic layer at 25-30ºC and stirred for 20 minutes. Layers
were separated. Distilled off the organic layer at below 45ºC and co-distilled with ethyl acetate.
Ethyl acetate (120.0 ml) was added to the obtained compound at 25-30ºC and stirred for 30
minutes. Ethyl acetate-hydrochloric acid (100.0 ml) was added to the mixture at 25-30ºC and
stirred for 90 minutes. Ethyl acetate (100.0 ml) was added to the mixture at 25-30ºC and stirred
for 1 hour. Filtered the solid, washed with ethyl acetate and dried to get the title compound.
Yield: 13.6 gm
HPLC purity: 99.76%
HCl content: 10.61 %
The PXRD pattern of the obtained compound is as illustrated in figure-1.

Example-3:

Preparation

of

crystal

modification

3

of

(R)-3-(4-(7H-

pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
hydrochloride of Formula-1.
Water (3.0 Lt) was added to (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol1-yl)-3-cyclopentylpropanenitrile phosphate of formula-3 (4.0 Kg) at 25-30ºC and stirred for
10 minutes. Dichloromethane (6.0 Lt) was added to the mixture at 25-30ºC and stirred for 30
minutes. Sodium carbonate solution was slowly added to mixture at 25-30ºC and stirred for 20
minutes. Layers were separated. Water (21.0 Lt) was added to organic layer at 25-30ºC and
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stirred for 20 minutes. Layers were separated. Water (28.0 Lt) was added to organic layer at
25-30ºC and stirred for 20 minutes. Layers were separated. Distilled off the organic layer at
below 45ºC and co-distilled with ethyl acetate. Ethyl acetate (48.0 Lt) was added to the
obtained compound at 25-30ºC and stirred for 10 minutes. Filtered the mixture through online
filter and cartridge filter and washed the filtrate with ethyl acetate. Ethyl acetate-hydrochloric
acid (49.0 Lt) was added to the mixture at 25-30ºC and stirred for 3 hours. Ethyl acetate (56.0
Lt) was added to the mixture at 25-30ºC and stirred for 90 minutes. Filtered the solid, washed
with ethyl acetate and dried to get the title compound.
Yield: 1.09 Kg
HPLC purity: 99.83%
HCl content: 10.62 %
The PXRD pattern of the obtained compound is as illustrated in figure-2.

*********
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